See more : Mountain Alliance AG (ECF.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Kyowa Kirin Co., Ltd. (KYKOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyowa Kirin Co., Ltd., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- GTPL Hathway Limited (GTPL.BO) Income Statement Analysis – Financial Results
- Kardan Real Estate Enterprise and Development Ltd (KARE.TA) Income Statement Analysis – Financial Results
- StemRIM (4599.T) Income Statement Analysis – Financial Results
- Satori Electric Co., Ltd. (7420.T) Income Statement Analysis – Financial Results
- Kunimine Industries Co., Ltd. (5388.T) Income Statement Analysis – Financial Results
Kyowa Kirin Co., Ltd. (KYKOF)
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 442.23B | 398.37B | 352.25B | 318.35B | 305.82B | 346.53B | 353.38B | 343.02B | 364.32B | 333.45B | 340.61B | 333.16B | 343.72B | 413.74B | 0.00 | 392.12B | 354.27B | 353.44B | 358.96B | 348.84B | 359.29B | 378.67B | 375.61B | 374.91B |
| Cost of Revenue | 111.21B | 86.92B | 87.85B | 80.44B | 79.62B | 119.34B | 129.06B | 134.53B | 138.92B | 127.54B | 127.85B | 122.47B | 146.17B | 222.76B | 0.00 | 247.20B | 222.85B | 226.46B | 226.85B | 219.33B | 232.96B | 249.92B | 251.67B | 248.04B |
| Gross Profit | 331.03B | 311.46B | 264.40B | 237.91B | 226.20B | 227.19B | 224.32B | 208.49B | 225.39B | 205.90B | 212.76B | 210.69B | 197.56B | 190.98B | 0.00 | 144.92B | 131.43B | 126.98B | 132.11B | 129.51B | 126.33B | 128.74B | 123.95B | 126.87B |
| Gross Profit Ratio | 74.85% | 78.18% | 75.06% | 74.73% | 73.97% | 65.56% | 63.48% | 60.78% | 61.87% | 61.75% | 62.46% | 63.24% | 57.48% | 46.16% | 0.00% | 36.96% | 37.10% | 35.93% | 36.80% | 37.13% | 35.16% | 34.00% | 33.00% | 33.84% |
| Research & Development | 81.51B | 62.90B | 57.68B | 52.31B | 53.51B | 48.59B | 49.16B | 53.79B | 51.52B | 47.67B | 43.63B | 44.78B | 47.93B | 44.06B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 133.23B | 166.19B | 145.61B | 126.61B | 117.32B | 119.81B | 112.96B | 0.00 | 0.00 | 169.00M | 205.00M | 145.00M | 132.00M | 0.00 | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Selling & Marketing | 29.85B | 47.33B | 38.56B | 30.28B | 24.03B | 19.48B | 13.71B | 15.86B | 16.71B | 15.96B | 16.42B | 15.19B | 15.27B | 15.66B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 163.08B | 166.19B | 145.61B | 126.61B | 117.32B | 119.81B | 112.96B | 15.86B | 16.71B | 15.96B | 16.42B | 15.19B | 15.40B | 15.66B | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Other Expenses | 0.00 | -21.36B | -5.63B | -9.19B | -14.58B | 15.50B | -1.76B | 753.00M | 255.00M | -141.00M | -392.00M | -1.00M | -124.00M | 1.13B | 0.00 | -2.05B | 0.00 | -1.47B | -4.05B | -11.44B | 0.00 | -5.61B | 6.09B | 2.06B |
| Operating Expenses | 244.59B | 229.08B | 203.29B | 178.92B | 170.83B | 168.40B | 162.11B | 176.85B | 181.62B | 169.73B | 160.98B | 157.78B | 112.90B | 106.73B | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Cost & Expenses | 355.79B | 316.00B | 291.14B | 259.36B | 250.45B | 287.74B | 291.17B | 311.38B | 320.55B | 297.27B | 288.83B | 280.25B | 259.06B | 329.49B | 0.00 | 352.73B | 323.58B | 327.91B | 325.46B | 322.00B | 343.20B | 358.31B | 357.90B | 353.25B |
| Interest Income | 4.87B | 3.32B | 1.11B | 1.80B | 1.03B | 839.00M | 806.00M | 476.00M | 459.00M | 629.00M | 775.00M | 604.00M | 497.00M | 362.00M | 0.00 | 1.80B | 528.00M | 1.17B | 995.00M | 686.00M | 781.00M | 778.00M | 827.00M | 798.00M |
| Interest Expense | 190.00M | 1.09B | 1.12B | 299.00M | 1.31B | 1.59B | 931.00M | 42.00M | 59.00M | 145.00M | 259.00M | 205.00M | 135.00M | 199.00M | 0.00 | 328.00M | 240.00M | 186.00M | 240.00M | 804.00M | 1.72B | 3.11B | 3.13B | 2.72B |
| Depreciation & Amortization | 17.19B | 18.48B | 19.50B | 20.47B | 18.80B | 16.24B | 22.03B | 23.78B | 36.56B | 36.71B | 33.17B | 32.93B | 33.55B | 32.12B | 0.00 | 14.35B | 10.01B | 9.79B | 10.57B | 11.36B | 14.77B | 17.82B | 18.50B | 19.38B |
| EBITDA | 113.04B | 87.14B | 79.86B | 74.71B | 70.83B | 84.47B | 84.53B | 67.06B | 80.33B | 72.88B | 84.94B | 78.16B | 79.86B | 74.61B | 0.00 | 60.10B | 53.49B | 33.77B | 34.85B | 40.71B | 33.54B | 33.48B | 33.40B | 43.51B |
| EBITDA Ratio | 25.56% | 21.87% | 22.90% | 22.94% | 21.12% | 28.06% | 22.30% | 18.87% | 20.76% | 20.35% | 24.64% | 25.15% | 34.51% | 28.44% | 0.00% | 14.45% | 11.34% | 10.50% | 12.66% | 15.05% | 9.34% | 13.98% | 13.41% | 11.48% |
| Operating Income | 86.44B | 68.66B | 61.17B | 52.56B | 45.80B | 75.03B | 57.73B | 31.64B | 43.77B | 36.17B | 51.77B | 52.91B | 85.08B | 45.41B | 0.00 | 39.39B | 30.16B | 25.54B | 33.51B | 26.84B | 18.78B | 20.36B | 17.71B | 21.66B |
| Operating Income Ratio | 19.55% | 17.24% | 17.36% | 16.51% | 14.98% | 21.65% | 16.34% | 9.22% | 12.01% | 10.85% | 15.20% | 15.88% | 24.75% | 10.98% | 0.00% | 10.05% | 8.51% | 7.22% | 9.33% | 7.69% | 5.23% | 5.38% | 4.72% | 5.78% |
| Total Other Income/Expenses | 10.81B | 2.76B | -1.06B | -299.00M | -1.31B | -1.59B | -1.88B | -1.35B | -2.37B | -8.93B | -2.00B | -7.88B | -38.89B | -3.11B | 0.00 | -14.45B | -575.00M | -2.01B | -663.00M | -3.60B | -3.40B | 904.00M | -7.90B | 215.00M |
| Income Before Tax | 97.25B | 67.57B | 60.05B | 52.26B | 44.49B | 73.44B | 55.85B | 30.29B | 41.40B | 27.25B | 49.77B | 45.03B | 46.18B | 42.30B | 0.00 | 38.82B | 23.53B | 24.87B | 29.90B | 15.38B | 16.99B | 12.46B | 21.87B | 22.58B |
| Income Before Tax Ratio | 21.99% | 16.96% | 17.05% | 16.42% | 14.55% | 21.19% | 15.80% | 8.83% | 11.36% | 8.17% | 14.61% | 13.51% | 13.44% | 10.22% | 0.00% | 9.90% | 6.64% | 7.04% | 8.33% | 4.41% | 4.73% | 3.29% | 5.82% | 6.02% |
| Income Tax Expense | 16.06B | 14.00B | 7.70B | 5.24B | 6.82B | 19.03B | 12.95B | 11.62B | 11.63B | 11.35B | 19.60B | 20.61B | 20.49B | 20.04B | 0.00 | 15.19B | 10.87B | 8.49B | 11.90B | 5.53B | 8.48B | 6.99B | 12.74B | 11.49B |
| Net Income | 81.19B | 53.57B | 52.35B | 47.03B | 67.08B | 54.41B | 42.90B | 18.67B | 29.77B | 15.90B | 30.08B | 24.20B | 25.61B | 22.20B | 0.00 | 23.48B | 12.69B | 16.27B | 17.93B | 10.02B | 8.49B | 5.54B | 9.40B | 11.27B |
| Net Income Ratio | 18.36% | 13.45% | 14.86% | 14.77% | 21.94% | 15.70% | 12.14% | 5.44% | 8.17% | 4.77% | 8.83% | 7.26% | 7.45% | 5.36% | 0.00% | 5.99% | 3.58% | 4.60% | 5.00% | 2.87% | 2.36% | 1.46% | 2.50% | 3.01% |
| EPS | 151.01 | 99.68 | 97.43 | 87.56 | 124.57 | 100.95 | 78.38 | 34.11 | 54.40 | 29.05 | 54.95 | 44.12 | 45.16 | 38.96 | 0.00 | 59.03 | 31.32 | 38.48 | 41.93 | 23.21 | 19.56 | 12.75 | 21.64 | 25.96 |
| EPS Diluted | 151.01 | 99.66 | 97.39 | 87.50 | 124.46 | 100.95 | 78.30 | 34.08 | 54.36 | 29.02 | 54.91 | 44.10 | 45.14 | 38.94 | 0.00 | 59.03 | 31.32 | 38.30 | 41.93 | 23.21 | 19.56 | 12.75 | 21.64 | 25.90 |
| Weighted Avg Shares Out | 537.63M | 537.43M | 537.27M | 537.11M | 538.54M | 539.01M | 547.29M | 547.29M | 547.29M | 547.35M | 547.39M | 548.45M | 567.03M | 569.71M | 570.94M | 397.72M | 405.27M | 422.92M | 427.64M | 431.50M | 433.75M | 434.24M | 434.24M | 434.24M |
| Weighted Avg Shares Out (Dil) | 537.63M | 537.57M | 537.51M | 537.48M | 539.01M | 539.01M | 547.86M | 547.86M | 547.72M | 547.83M | 547.77M | 548.73M | 567.30M | 570.03M | 570.94M | 397.72M | 405.27M | 424.88M | 427.64M | 431.50M | 433.75M | 434.24M | 434.24M | 435.29M |
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company
Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States
Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies
Source: https://incomestatements.info
Category: Stock Reports